Idoxuridine

Antiviral Nucleoside analog (thymidine analog)

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Cat Ophthalmic (topical) 1 drop of 0.1% solution or 0.5% ointment Every 4-6 hours (q4-6h) Duration: Until clinical resolution, typically 7-14 days
Notes: Apply to affected eye(s). Avoid contact with contact lenses. May cause stinging.
Horse Ophthalmic (topical) 1 drop of 0.1% solution or 0.5% ointment Every 4-6 hours (q4-6h) Duration: Until clinical resolution, typically 7-14 days
Notes: Apply to affected eye(s). Use caution to avoid trauma to the eye.
Cattle Ophthalmic (topical) 1 drop of 0.1% solution or 0.5% ointment Every 4-6 hours (q4-6h) Duration: Until clinical resolution, typically 7-14 days
Notes: Not commonly used; consider other antiviral options.

Clinical Indications & Species Uses

General Indications
  • Topical treatment of herpesvirus keratitis and conjunctivitis in companion animals
Cat (Feline)
  • Feline herpesvirus-1 keratitis and conjunctivitis (topical ophthalmic)
Horse (Equine)
  • Equine herpesvirus keratitis (topical ophthalmic)

Pharmacology & Mechanism of Action

Drug Class: Antiviral | Pharmacological Group: Nucleoside analog (thymidine analog)

Mechanism of Action: Idoxuridine is a halogenated thymidine analog that inhibits viral DNA replication. It is phosphorylated by viral thymidine kinase to idoxuridine monophosphate, which is then further phosphorylated to the triphosphate form. The triphosphate is incorporated into viral DNA, causing faulty DNA synthesis and premature chain termination. It also inhibits viral DNA polymerase, leading to inhibition of viral replication. Its selectivity is based on higher affinity for viral thymidine kinase compared to host cellular thymidine kinase, though it can also affect host cells at higher concentrations.

Pharmacodynamics: Idoxuridine is virustatic against DNA viruses, particularly herpesviruses (e.g., feline herpesvirus-1, bovine herpesvirus-1, equine herpesvirus-1) and poxviruses. It has minimal activity against RNA viruses. Its efficacy is limited by rapid metabolism and poor tissue penetration. In veterinary medicine, it is primarily used topically for ocular infections due to its poor systemic tolerability and low therapeutic index.

⚡ Pharmacokinetics Summary

Absorption: When applied topically to the eye, idoxuridine penetrates the cornea and reaches therapeutic concentrations in the aqueous humor. Systemic absorption is minimal after ocular administration. Oral absorption is poor and erratic; systemic administration is not used due to severe toxicity.
Distribution: Following topical ocular application, it distributes into the corneal epithelium and stroma. Systemic distribution is not clinically relevant due to lack of systemic use. If absorbed systemically, it would distribute widely but is rapidly metabolized.
Metabolism: Idoxuridine is rapidly metabolized in the liver and other tissues by dehalogenation and glucuronidation. The metabolites are inactive. Its half-life is short due to rapid metabolism.
Excretion: Metabolites are excreted primarily in the urine. After ocular application, a small amount may be absorbed and excreted renally.
Half-Life: Ocular: approximately 30 minutes in the tear film; systemic: very short (minutes) due to rapid metabolism.
Bioavailability: Ocular: adequate corneal penetration; systemic: negligible due to poor absorption and first-pass metabolism.
Protein Binding: Not well characterized; likely low due to rapid metabolism.

Available Formulations & Strengths

Ophthalmic Solution 0.1% (Ophthalmic)
Ophthalmic Ointment 0.5% (Ophthalmic)

Contraindications & Clinical Warnings

Contraindications:
  • Hypersensitivity to idoxuridine or any component of the formulation
  • Systemic use (due to severe toxicity)
  • Known allergy to iodine-containing compounds (cross-reactivity possible)
Warnings & Clinical Precautions:
  • For ophthalmic use only; not for injection or systemic use.
  • May cause local irritation, stinging, or burning upon application.
  • Prolonged use may cause corneal epithelial toxicity or delayed wound healing.
  • Use with caution in pregnant or lactating animals; safety not established.
  • Do not use in animals with known corneal perforation or deep ulceration unless directed by a veterinarian.
  • Wash hands after administration; avoid contamination of the dropper tip.

Adverse Effects & Reactions

Common:

  • Local stinging or burning
  • Transient blurred vision
  • Lacrimation
  • Conjunctival hyperemia

Serious / Severe:

  • Corneal epithelial toxicity
  • Corneal ulceration (with prolonged use)
  • Delayed corneal wound healing
  • Allergic reactions (rare)

Rare:

  • Systemic toxicity (if absorbed in large amounts)
  • Contact dermatitis

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Corticosteroids (topical ophthalmic) Corticosteroids may suppress the antiviral activity of idoxuridine and exacerbate viral infections; concurrent use is generally contraindicated. High
Boric acid (in ophthalmic preparations) Boric acid may cause precipitation of idoxuridine; avoid concurrent use. Moderate
Other topical ophthalmic medications May cause physical incompatibility; separate administration by at least 5 minutes. Mild

Overdose & Toxicity Management

Signs of Toxicity:

  • Local irritation
  • Corneal epithelial damage
  • Excessive lacrimation
  • If ingested: gastrointestinal upset, bone marrow suppression (theoretical)

Emergency Treatment Protocol: For ocular overdose, flush the eye with sterile saline or artificial tears. For accidental ingestion, induce vomiting if recent and perform supportive care. Monitor for systemic toxicity. There is no specific antidote.

Food Animal Withdrawal Times

Not approved for food animals; withdrawal times not established. Use in food animals is off-label and prohibited in some jurisdictions.

Storage, Handling & Regulatory Information

Storage Temperature: Store at room temperature 15-30°C (59-86°F). Protect from light.

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Keep container tightly closed. Do not freeze. Discard after expiration date.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for human ophthalmic use; not FDA-approved for veterinary use, but may be used off-label in animals.

Extra-Label (Off-Label) Use: In the US, extra-label use in food animals is prohibited under AMDUCA if an approved drug exists. In companion animals, extra-label use is permitted with veterinary oversight.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Idoxuridine is an antiviral agent primarily used topically for herpesvirus ocular infections in cats, horses, and occasionally other species. It is most effective when initiated early in the course of infection. Due to its potential for corneal toxicity with prolonged use, treatment should be limited to the duration of clinical signs. Alternative antivirals such as trifluridine or cidofovir may be preferred in some cases. Always confirm the diagnosis and rule out other causes of keratitis. Monitor for adverse effects and discontinue if severe irritation occurs.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)